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StatinsSeveral well-established and new cardiovascular risk factors have
been related to the occurrence and progression of cardiovascular dis-
ease (CVD) [1,2]. Early detection of the disease in the coronary arteries
by means of non-invasive and invasive imaging is highly desirable to
better stratify the risk of a patient for a coronary event.
A catheter-based near-infrared spectroscopy system (NIRS) (Infra-
ReDx, Burlington, USA) is a novel imagingmodality that determines tis-
sue composition [3,4]. This intra-coronary system utilizes the variation
in reﬂection of the emitted near-infrared light to detect vulnerable
lipid-core containing plaques (LCP), visible as a “yellow spot”, and pro-
vides two quantitative measurements, namely a (block) chemogram
and a lipid-core burden index (LCBI) score [5]. The identiﬁcation and
measurement of these modalities could serve as important parameters
in the prevention and treatment of CVD, since there is a close relation-
ship between vulnerable plaque and cardiovascular events [6]. The
intake of a high dose statin could improve these NIRS-derived parame-
ters of a non-intervened coronary artery segment. We present a case
that illustrates the results of this concept.
Case 1: A 44-year oldmanwith inferior wall ST-elevationmyocardi-
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Open access under the Elsevier OA license.ous coronary intervention (PCI). He had no cardiac history and the
known cardiac risk factors were hypertension, hypercholesterolemia
and obesity (BMI of 33.9 kg/m2). The lipid proﬁle of the statin-naïve pa-
tient was an LDL-cholesterol level of 4.0 mmol/L (upper limit of
4.1 mmol/L), HDL-cholesterol level of 1.0 mmol/L (lower limit of
1.55 mmol/L) and a total cholesterol/HDL-cholesterol ratio of 5.7
(upper limit of 4.0).
The thrombus in the left anterior descending coronary artery seg-
ment 6 was aspirated (Medtronic, Minneapolis, USA) and subsequently
treated with an everolimus-eluting 3.5×18 mm stent (XIENCE V,
Abbott vascular systems, Santa Clara, USA). Angiography of the co-
dominant right coronary artery showed a lesion in segment 3 for
which a staged PCI-procedure was planned ﬁve days later (Fig. 1). The
NIRS-catheter was used to make images proximal of the implanted
stent in the right coronary artery (Fig. 1). The patient had a baseline
LCBI score of 114. One week after the procedure, the patient was seen
in the outpatient clinic, where a daily dose of 40 mg of rosuvastatin
was prescribed as part of the IBIS-3 study, for which the patient provid-
ed informed consent [7]. After 1 year of highdose rosuvastatin treatment,
the lipid proﬁle had improved when compared to baseline. The LDL-
cholesterol level decreased to 2.8 mmol/L (−30%), the HDL-cholesterol
level increased to 1.3 mmol/L (+30%) and the total cholesterol/HDL-
cholesterol ratio improved from 5.7 to 3.4 (−40%). The diagnostic cathe-
terization after 1 year, scheduled as part of the IBIS-3 study, showed no
lesions in the coronary arteries or in-stent restenosis. The LCBI score of
the matched region of interest was reduced from 114 to 14 (Fig. 1). The
amount of the “tanned” block chemograms was reduced from 11 to 2. A
yellow spot appeared in the chemogram on an initially non-LCP contain-
ing location (Fig. 1).
The amount of LCP for each scanned arterial segment in the region
of interest is displayed as a chemogram, with the x-axis indicating the
pullback position in millimeters and the y-axis the circumferential
position of the measurement in degrees, while the probability of
LCP present is coded on a color scale from red to yellow (0 for red
and 1 for yellow). The chemogram block utilizes a binned color
scale, in which pixels that are exceeding a pre-speciﬁed threshold of
60% turn to yellow, which is representative of a LCP. The LCBI score
summarizes the fraction of LCP in the imaged section of the coronary
vessel on a 0-to-1000 scale. Our previous study showed that (1) pla-
ques coded as yellow were associated with signiﬁcantly larger plaque
size (mm2) compared to those coded as red and that (2) plaque
coded as yellow was weakly correlated with more necrotic core as
assessed with virtual histology-intravascular ultrasound [8]. A recent
Fig. 1. (A) The right coronary artery showing a signiﬁcant lesion in segment 3. (B) The lesion in the right coronary artery has been treated with a Xience V 2.5×12 mm stent.
(C1) Baseline lipiscan landmarks, correlating with the chemogram in C2. (D1) The follow-up lipiscan landmarks are matched with the index procedure. The chemogram in D2
shows a decrease in the LCBI score compared with the baseline LCBI score.
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syndrome tended to be higher than of patients with stable angina
(82 vs. 57, P=0.05) [5]. The baseline LCBI score of 114 of our patient
could therefore be classiﬁed as relatively high.
It has been shown that the inter-catheter reproducibility of NIRS
for the detection of coronary lipid core plaques is high and that
NIRS is suitable to assess the status of LCP over time and in response
to novel treatment [9]. The usage of a high dose rosuvastatin did not
only improve the lipid proﬁle of the statin-naive patient, but also led
to an evident decrease in LCBI score of the non-intervened coronary
artery segment. Noteworthy is the appearance of a LCP in a previously
non-lipid core containing plaque region. Whether this is an unidenti-
ﬁed LCP at baseline or a newly formed LCP is unknown. The effect of a
high dose rosuvastatin on the LCP is currently being studied in the
IBIS-3 study [7].Acknowledgement
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